KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

BMC Cancer

Table 1 Clinico-pathological profile and the KIBRA expression of the study cohort

Clinico-pathological features	n	%	Clinico-pathological features	n	%
Histological type			Lympho-vascular invasion
Invasive duct (NOS)	1081	96.3	Presence	452	43.2
Invasive lobular	17	1.5	Absence	595	56.8
Mucinous	4	0.4	Unknown	77
Other types	20	1.8
Unknown	2		Expression of ER
Age at presentation			Positive	525	46.7
< =35 years	74	6.6	Negative	598	53.3
36–60 years	729	65.1	Unknown	1
> 60 years	317	28.3	Expression of PgR
Unknown	4		Positive	513	46.0
Tumour size			Negative	602	54.0
< 20 mm	376	33.8	Unknown	9
> 20-50 mm	637	57.2	Expression of HER2
> 50 mm	101	9.0	Positive	219	21.0
Unknown	10		Negative	823	79.0
Nottingham grade			Borderline	72
Grade 1	141	13.5	Unknown	10
Grade 2	505	48.4	Molecular classification
Grade 3	398	38.1	luminal A	278	26.8
Unknown	80		luminal B (Her2 negative)	126	12.2
Lymph node stage			luminal B (Her2 positive)	66	6.4
Stage 0	543	48.4	Her2-enriched	153	14.8
Stage 1	274	24.4	TNBC	329	31.8
Stage 2	182	16.2	Basal-like	84	8.1
Stage 3	123	11
Unknown	2
TNM stage			KIBRA expression
I	165	16.0	Cytoplasm + nuclei	234	25.7
II	478	46.5	Only cytoplasm	125	13.7
III	377	36.7	Only nuclei	173	19.0
IV	8	0.8	Overall KIBRA-Low	377	41.5
Unknown	96		Unknown	215

n number, % percentage, NOS not otherwise specified, TNM tumour-node-metastasis, ER estrogen receptors, PgR progesterone receptors, HER2 human epidermal growth factor receptor2

ISSN: 1471-2407